MX2021013576A - Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo. - Google Patents
Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo.Info
- Publication number
- MX2021013576A MX2021013576A MX2021013576A MX2021013576A MX2021013576A MX 2021013576 A MX2021013576 A MX 2021013576A MX 2021013576 A MX2021013576 A MX 2021013576A MX 2021013576 A MX2021013576 A MX 2021013576A MX 2021013576 A MX2021013576 A MX 2021013576A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitor
- application
- compound used
- racemate
- meso
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
En la presente se proporciona el compuesto representado por la fórmula I, o tautómero del mismo, o mesómero del mismo, racemato del mismo, y mezcla del mesómero y el racemato del mismo, o enantiómero del mismo, diastereoisómero, y mezcla del enantiómero y el diastereoisómero, o sal farmacéuticamente aceptable del mismo, o deuterado del mismo. El compuesto de fórmula I se puede utilizar como inhibidor de quinasas, como fármaco para el tratamiento de ROS1, NTRK, ALK y otras enfermedades mediadas por quinasas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910379104 | 2019-05-08 | ||
PCT/CN2020/089067 WO2020224626A1 (zh) | 2019-05-08 | 2020-05-07 | 用作激酶抑制剂的化合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021013576A true MX2021013576A (es) | 2021-12-15 |
Family
ID=73051434
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021013576A MX2021013576A (es) | 2019-05-08 | 2020-05-07 | Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220089603A1 (es) |
EP (1) | EP3967696A4 (es) |
JP (1) | JP7420403B2 (es) |
KR (1) | KR20220007111A (es) |
CN (1) | CN112867717B (es) |
AU (1) | AU2020270303B2 (es) |
BR (1) | BR112021022255A2 (es) |
CA (1) | CA3142088C (es) |
IL (1) | IL287908A (es) |
MX (1) | MX2021013576A (es) |
SG (1) | SG11202112381VA (es) |
WO (1) | WO2020224626A1 (es) |
ZA (1) | ZA202109737B (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114437077B (zh) * | 2020-11-04 | 2024-01-30 | 浙江同源康医药股份有限公司 | 用作激酶抑制剂的化合物及其应用 |
CN114957259A (zh) * | 2021-02-25 | 2022-08-30 | 南京明德新药研发有限公司 | 氰基取代的芳香双环类化合物及其应用 |
WO2022262671A1 (zh) * | 2021-06-15 | 2022-12-22 | 中国医药研究开发中心有限公司 | 杂环大环化合物及其医药用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005042742A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并[1,2-b]嗒衍生物 |
WO2013189905A1 (en) | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | Pyrrolopyrazone inhibitors of tankyrase |
UY34893A (es) | 2012-07-10 | 2014-02-28 | Takeda Pharmaceutical | Derivados de azaindol |
KR102659741B1 (ko) | 2014-12-15 | 2024-04-23 | 주식회사 씨엠지제약 | 융합된 고리 헤테로아릴 화합물 및 trk 억제제로서의 이들의 용도 |
CN111171019A (zh) * | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
TW202033526A (zh) * | 2018-12-07 | 2020-09-16 | 大陸商貝達藥業股份有限公司 | 用作酪胺酸激酶抑制劑的化合物、包含其的藥物組合物及其用途 |
-
2020
- 2020-05-07 CA CA3142088A patent/CA3142088C/en active Active
- 2020-05-07 SG SG11202112381VA patent/SG11202112381VA/en unknown
- 2020-05-07 KR KR1020217040056A patent/KR20220007111A/ko not_active Application Discontinuation
- 2020-05-07 MX MX2021013576A patent/MX2021013576A/es unknown
- 2020-05-07 AU AU2020270303A patent/AU2020270303B2/en active Active
- 2020-05-07 BR BR112021022255A patent/BR112021022255A2/pt unknown
- 2020-05-07 JP JP2021566283A patent/JP7420403B2/ja active Active
- 2020-05-07 CN CN202080004473.2A patent/CN112867717B/zh active Active
- 2020-05-07 WO PCT/CN2020/089067 patent/WO2020224626A1/zh unknown
- 2020-05-07 EP EP20802185.7A patent/EP3967696A4/en active Pending
-
2021
- 2021-11-08 US US17/521,153 patent/US20220089603A1/en active Pending
- 2021-11-08 IL IL287908A patent/IL287908A/en unknown
- 2021-11-29 ZA ZA2021/09737A patent/ZA202109737B/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3967696A4 (en) | 2023-08-09 |
US20220089603A1 (en) | 2022-03-24 |
CA3142088C (en) | 2023-02-28 |
SG11202112381VA (en) | 2021-12-30 |
IL287908A (en) | 2022-01-01 |
AU2020270303A1 (en) | 2022-01-06 |
WO2020224626A1 (zh) | 2020-11-12 |
CN112867717A (zh) | 2021-05-28 |
JP7420403B2 (ja) | 2024-01-23 |
KR20220007111A (ko) | 2022-01-18 |
JP2022532141A (ja) | 2022-07-13 |
AU2020270303B2 (en) | 2023-09-07 |
EP3967696A1 (en) | 2022-03-16 |
CA3142088A1 (en) | 2020-11-12 |
WO2020224626A9 (zh) | 2020-12-30 |
BR112021022255A2 (pt) | 2022-01-18 |
ZA202109737B (en) | 2022-07-27 |
CN112867717B (zh) | 2023-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2018000319A1 (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
MX2021007970A (es) | Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. | |
MY194405A (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
MX2021013576A (es) | Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo. | |
MX358311B (es) | Compuesto heterociclico que contiene nitrogeno o sal del mismo. | |
MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
PH12017501570B1 (en) | Bicyclic ketone sulfonamide compounds | |
PH12016500531B1 (en) | Compound inhibiting activities of btk and/or jak3 kinases | |
AU2018251118A8 (en) | Pharmaceutical composition containing MOR agonist and KOR agonist, and uses thereof | |
MX2007004248A (es) | Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa. | |
PH12020552017A1 (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
PH12019500036A1 (en) | Heterocyclic compound used as fgfr inhibitor | |
EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
BR112022008786A2 (pt) | Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose | |
PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
MX2022003504A (es) | Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo. | |
MX2019006612A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta). | |
MX2021012105A (es) | Compuestos de pirrol. | |
PH12020551343A1 (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
MX2021009539A (es) | Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof |